Sign in Subscribe
Securities law

Securities Lawsuit Filed Against Rocket Pharmaceuticals, Inc.

Strategic Insights

— 1 min read

A class action securities lawsuit was filed against Rocket Pharmaceuticals, Inc., alleging that the company made false and misleading statements to investors regarding the safety and clinical trial protocol of its drug candidate RP-A501. The lawsuit seeks to recover losses of shareholders who were affected by the alleged securities fraud between September 17, 2024, and May 26, 2025. The complaint alleges that Rocket knew about the risks of Serious Adverse Events (SAEs), including death of participants enrolled in the study, but failed to disclose this information to shareholders. The company's stock price declined dramatically after the FDA placed a clinical hold on the RP-A501 Phase 2 pivotal study, resulting in a loss of over 37% in a single trading day.

Key Takeaways:

  • A class action securities lawsuit was filed against Rocket Pharmaceuticals, Inc. on May 27, 2025, alleging securities fraud between September 17, 2024, and May 26, 2025.
  • The lawsuit seeks to recover losses of shareholders who were affected by the alleged securities fraud.
  • Rocket allegedly made false and misleading statements to investors regarding the safety and clinical trial protocol of its drug candidate RP-A501.
  • The company knew about the risks of Serious Adverse Events (SAEs), including death of participants enrolled in the study, but failed to disclose this information to shareholders.
  • The company's stock price declined dramatically after the FDA placed a clinical hold on the RP-A501 Phase 2 pivotal study, resulting in a loss of over 37% in a single trading day.
  • Levi & Korsinsky LLP, a nationally-recognized securities litigation firm, is representing the plaintiff in the lawsuit.
  • The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees.

Statistics:

  • The lawsuit was filed on May 27, 2025
  • The alleged securities fraud occurred between September 17, 2024, and May 26, 2025
  • The company's stock price declined by 37% in a single trading day
  • The price of Rocket's common stock fell from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025.

Sources:

  • https://zlk.com/pslra-1/rocket-pharmaceuticals-inc-lawsuit-submission-form?prid=158926&wire=5&utm_campaign=11
  • https://www.youtube.com/watch?v=bar7Q9XIFkc
  • https://zlk.com/

Read more